STAT

Do Elon Musk’s brain-decoding implants have potential? Experts say they just might

Do Elon Musk’s brain-decoding implants have potential? Independent experts consulted by STAT say they very well might.

SAN FRANCISCO — Okay, the “sewing machine” is pretty cool. But if the device that Elon Musk’s neurotechnology startup Neuralink developed to implant thousands of electrodes into brains (of rats and monkeys so far, and humans eventually) were its only accomplishment, Tuesday night’s big reveal would have been a big meh. Instead, six independent experts in the kind of brain-computer interfaces that Neuralink is developing told STAT they are impressed for the most part, though caveats abound.

“Overall, the concept is impressive and so is the progress they’ve made,” said neurobiologist Andrew Schwartz of the University of Pittsburgh Medical Center, a pioneer in the technology. “But a lot of this still seems to be conceptual. It’s hard to tell what’s aspirational and what they’ve actually done.”

The immediate aim of the San Francisco startup is a system enabling people who are paralyzed to use their thoughts to operate computers and smartphones. That has been done before, including by Schwartz’s group and one at Brown University, where in 2011 two tetraplegic patients who had been implanted with the “BrainGate” neural

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Sanofi Licensing Novavax’s Covid Shot, Moderna’s RSV Vaccine, And More
Sanofi said it has reached a licensing deal to sell Novavax’s Covid shot as well as to try to combine the vaccine with Sanofi’s own flu vaccine.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks